Contents

Editorial
Cancer Risk Before Schizophrenia Diagnosis in Taiwan, 1995–2009 ................................. 729
Yu-Jung Chen, Gen-Min Lin, and Yi-Hwei Li

Special Features
First Person Account
“Poetry in Yarn”—Making Sense of Life Experiences in the Shadow of Schizophrenia ................. 732
Lis Bodil Karlsson and Annika Malmqvist

Schizophrenia in Translation—Feature Editor: Thomas McGlashan
Translating Basic Emotion Research Into Novel Psychosocial Interventions for Anhedonia .......... 737
Gregory P. Strauss

Environment and Schizophrenia—Feature Editor: Jim van Os
Life Events and Psychosis: A Review and Meta-analysis ......................................................... 740

Cochrane Corner—Feature Editor: Clive E. Adams
Preventive Interventions for Postnatal Psychosis ................................................................. 748
Adib Essali, Samer Alabed, Aisha Guul, and Norah Essali

At Issue
Lack of Use in the Literature From the Last 20 Years Supports Dropping Traditional Schizophrenia Subtypes From DSM-5 and ICD-11 ................................................................. 751
David L. Braff, James Ryan, Anthony J. Rissling, and William T. Carpenter

Theme: Major Depressive Disorder With Psychotic Features: Neglected Clues to the Pathobiology and Dimensionality of Psychotic Illness
Guest Editors: John L. Waddington and Peter F. Buckley

Theme Introduction
Psychotic Depression: An Underappreciated Window to Explore the Dimensionality and Pathobiology of Psychosis ................................................................. 754
John L. Waddington and Peter F. Buckley

Epidemiological and Clinical Characterization Following a First Psychotic Episode in Major Depressive Disorder: Comparisons With Schizophrenia and Bipolar I Disorder in the Cavan-Monaghan First Episode Psychosis Study (CAMFEPS) ................................................. 756
Olabisi Owoeye, Tara Kingston, Paul J. Scully, Patrizia Baldwin, David Browne, Anthony Kinsella, Vincent Russell, Eadhbard O’Callaghan, and John L. Waddington

Clinical and Molecular Genetics of Psychotic Depression .......................................................... 766
Katharina Domschke

Structural and Functional Neuroimaging Studies in Major Depressive Disorder With Psychotic Features: A Critical Review ................................................................. 776
Geraldo F. Busatto

Challenges in the Treatment of Major Depressive Disorder With Psychotic Features .................. 787
Anthony J. Rothschild
Regular Articles

The Incidence and Nature of Cerebellar Findings in Schizophrenia: A Quantitative Review of fMRI Literature
Ovidiu Lungu, Marc Barakat, Samuel Laventure, Karen Debas, Sébastien Proulx, David Luck, and Emmanuel Stip

Dopaminergic Function in the Psychosis Spectrum: An [18F]-DOPA Imaging Study in Healthy Individuals With Auditory Hallucinations
Oliver D. Howes, Paul Shotbolt, Michael Bloomfield, Kirstin Daalman, Arsime Demjaha, Kelly M. J. Diederens, Kemal Ibrahim, Euitae Kim, Philip McGuire, René S. Kahn, and Iris E. Sommer

How Frequent Are Radiological Abnormalities in Patients With Psychosis? A Review of 1379 MRI Scans
Iris E. Sommer, Gérard A. P. de Kort, Anne Lotte Meijsing, Paola Dazzan, Hilleke E. Hulshoff Pol, René S. Kahn, and Neeltje E. M. van Haren

Cortex Morphology in First-Episode Psychosis Patients With Neurological Soft Signs
Olivier Gay, Marion Plaze, Catherine Oppenheim, Sabine Mouchet-Mages, Raphaël Gaillard, Jean-Pierre Olié, Marie-Odile Krebs, and Arnaud Cachia

Polyunsaturated Fatty Acid Concentration Predicts Myelin Integrity in Early-Phase Psychosis
Bart D. Peters, Marise W. J. Machielsen, Wendela P. Hoen, Matthan W. A. Caan, Anil K. Malhotra, Philip R. Szeszko, Marinus Duran, Silvia D. Olabarriaga, and Liewe de Haan

Fragile Early Visual Percepts Mark Genetic Liability Specific to Schizophrenia
Scott R. Sponheim, Sarah M. Sass, Althea L. Noukki, and Bridget M. Hegeman

Intermediate Phenotype Analysis of Patients, Unaffected Siblings, and Healthy Controls Identifies VMAT2 as a Candidate Gene for Psychotic Disorder and Neurocognition
Claudia J. P. Simons and Ruud van Winkel

Antiherpes Virus–Specific Treatment and Cognition in Schizophrenia: A Test-of-Concept Randomized Double-Blind Placebo-Controlled Trial
Konasale M. Prasad, Shaun M. Eack, Matcheri S. Keshavan, Robert H. Yolken, Satish Iyengar, and Vishwajit L. Nimgaonkar

Increased Prevalence of Transglutaminase 6 Antibodies in Sera From Schizophrenia Patients
Nicola G. Cascella, Debby Santora, Patricia Gregory, Deanna L. Kelly, Alessio Fasano, and William W. Eaton

Emotion Regulation Abnormalities in Schizophrenia: Cognitive Change Strategies Fail to Decrease the Neural Response to Unpleasant Stimuli
Gregory P. Strauss, Emily S. Kappenman, Adam J. Culbreth, Lauren T. Catalano, Bern G. Lee, and James M. Gold

Testing the Psychopathology of Psychosis: Evidence for a General Psychosis Dimension
Ulrich Reininghaus, Stefan Priebe, and Richard P. Bentall

Reading in Schizophrenic Subjects and Their Nonsymptomatic First-Degree Relatives
Eryl O. Roberts, Frank A. Proudlock, Kate Martin, Michael A. Reveley, Mohammed Al-Uzri, and Irene Gottlob

When Functional Capacity and Real-World Functioning Converge: The Role of Self-Efficacy
Veronica Cardenas, Stephanie Abel, Christopher R. Bowie, Denisse Tiznado, Colin A. Depp, Thomas L. Patterson, Dilip V. Jeste, and Brent T. Mausbach

Beyond the Usual Suspects: Positive Attitudes Towards Positive Symptoms Is Associated With Medication Noncompliance in Psychosis
Steffen Moritz, Jerome Favrod, Christina Andreou, Anthony P. Morrison, Francesca Bohn, Ruth Veckenstedt, Peter Tonn, and Anne Karow

At Risk for Schizophrenic or Affective Psychoses? A Meta-Analysis of DSM/ICD Diagnostic Outcomes in Individuals at High Clinical Risk
Paolo Fusar-Poli, Andreas Bechdolf, Matthew John Taylor, Ilaria Bonoldi, William T. Carpenter, Alison Ruth Yung, and Philip McGuire
About the Cover

My name is Calen Pick, 31 years old, a Wyoming native currently living in Bozeman, Montana, with my wife, Megan, where I operate a small art studio. Besides being a prolific artist, I am a speaker for Bringchange2mind.org and have told my story, which outlines my experience with psychiatric illness, to thousands of people. I also touch upon the therapeutic value of art as a tool for recovery.

“Sometimes words cannot express the very essence of thought and feeling, art does it better.”